Please enable JavaScript to continue using this application.

Compare $RNAC vs $TRDA | Chartloom

Compare

$RNAC vs $TRDA

Cartesian Therapeutics Inc · Entrada Therapeutics Inc

RNAC

Cartesian Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Compare $RNAC vs $TRDA

Comparing Cartesian Therapeutics Inc and Entrada Therapeutics Inc

RNACCartesian Therapeutics Inc

TRDAEntrada Therapeutics Inc

RNACCartesian Therapeutics Inc

Market cap

$207M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

473.62x

Rev growth (TTM)

-20.7%

YTD performance

4.4%

52W performance

-31.0%

FCF yield

-37.9%

TRDAEntrada Therapeutics Inc

Market cap

$220M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.15x

Rev growth (TTM)

-94.1%

YTD performance

-43.6%

52W performance

-8.0%

FCF yield

-61.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNAC

TRDA

Detailed metrics comparison

RNAC

Cartesian Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Market Cap

RNAC$207M

TRDA$220M

Enterprise Value

RNAC$113M

TRDA$121M

Price

RNAC$7.06

TRDA$5.67

P/E Ratio

RNACN/A

TRDAN/A

P/S Ratio

RNAC140.34x

TRDA46.97x

EV/Sales

RNAC76.18x

TRDA25.79x

EV/EBITDA

RNAC0.00x

TRDA15.47x

P/B Ratio

RNAC296.12x

TRDA0.90x

P/FCF Ratio

RNACN/A

TRDAN/A

EV/FCF

RNAC-1.43x

TRDA-0.89x

PEG Ratio

RNACN/A

TRDAN/A

Forward P/E (NTM)

RNACN/A

TRDAN/A

Forward P/S (NTM)

RNAC473.62x

TRDA5.15x

Revenue (TTM)

RNAC$1M

TRDA$5M

Revenue Growth (YoY)

RNAC-20.7%

TRDA-94.1%

Forward Rev Growth

RNAC-14.0%

TRDA124.9%

Gross Margin (TTM)

RNAC0.0%

TRDA0.0%

Operating Margin (TTM)

RNAC0.0%

TRDA0.0%

EBITDA Margin (TTM)

RNAC-6503.1%

TRDA-3686.8%

Net Margin (TTM)

RNAC-10422.5%

TRDA-3537.7%

FCF Margin (TTM)

RNAC-5322.4%

TRDA-2883.2%

Net Income (TTM)

RNAC$-154M

TRDA$-166M

FCF (TTM)

RNAC$-79M

TRDA$-135M

EPS (TTM)

RNAC-$5.16

TRDA-$3.93

ROE (TTM)

RNAC-321582.0%

TRDA-5761.0%

ROA (TTM)

RNAC-4761.0%

TRDA-4654.0%

ROIC (TTM)

RNAC-321582.0%

TRDA-5761.0%

Cash

RNAC$148M

TRDA$99M

Debt

RNAC$53M

TRDA$0

Net Cash/Debt

RNAC$95M

TRDA$99M

Current Ratio (TTM)

RNAC7.48x

TRDA10.89x

Quick Ratio (TTM)

RNAC7.19x

TRDA10.47x

Debt/Equity (TTM)

RNAC0.28x

TRDA0.00x

Debt/Assets (TTM)

RNAC0.0%

TRDA0.0%

Interest Coverage (TTM)

RNACN/A

TRDAN/A

Net Debt/EBITDA (TTM)

RNAC0.00x

TRDA0.00x

Beta

RNAC0.74

TRDA-0.22

52W Performance

RNAC-31.0%

TRDA-8.0%

YTD Performance

RNAC4.4%

TRDA-43.6%

% from 52W High

RNAC-35.9%

TRDA-65.5%

% from 52W Low

RNAC26.0%

TRDA10.1%

Asset Turnover (TTM)

RNAC0.01x

TRDA0.01x

FCF Yield (TTM)

RNAC-37.9%

TRDA-61.4%

Earnings Yield (TTM)

RNAC-74.3%

TRDA-75.3%

Dividend Yield (TTM)

RNACN/A

TRDAN/A

Rule of 40

RNAC-5,343.1

TRDA-2,977.3

EV/GP/RG

RNACN/A

TRDAN/A

Ticker research

View RNAC research View TRDA research

Metric	RNAC Cartesian Therapeutics Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$207M	$220M
Enterprise Value	$113M	$121M
Price	$7.06	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	140.34x	46.97x
EV/Sales	76.18x	25.79x
EV/EBITDA	0.00x	15.47x
P/B Ratio	296.12x	0.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.43x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	473.62x	5.15x
Revenue & Growth
Revenue (TTM)	$1M	$5M
Revenue Growth (YoY)	-20.7%	-94.1%
Forward Rev Growth	-14.0%	124.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-6503.1%	-3686.8%
Net Margin (TTM)	-10422.5%	-3537.7%
FCF Margin (TTM)	-5322.4%	-2883.2%
Net Income (TTM)	$-154M	$-166M
FCF (TTM)	$-79M	$-135M
EPS (TTM)	-$5.16	-$3.93
ROE (TTM)	-321582.0%	-5761.0%
ROA (TTM)	-4761.0%	-4654.0%
ROIC (TTM)	-321582.0%	-5761.0%
Financial Health
Cash	$148M	$99M
Debt	$53M	$0
Net Cash/Debt	$95M	$99M
Current Ratio (TTM)	7.48x	10.89x
Quick Ratio (TTM)	7.19x	10.47x
Debt/Equity (TTM)	0.28x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.74	-0.22
52W Performance	-31.0%	-8.0%
YTD Performance	4.4%	-43.6%
% from 52W High	-35.9%	-65.5%
% from 52W Low	26.0%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.01x
FCF Yield (TTM)	-37.9%	-61.4%
Earnings Yield (TTM)	-74.3%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-5,343.1	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View RNAC research	View TRDA research

Valuation

P/S Ratio

TRDA

46.97x

RNAC

140.34x

EV/FCF

RNAC

-1.43x

TRDA

-0.89x

Growth & revenue

Revenue Growth TTM

RNAC

-20.7%

TRDA

-94.1%

Forward Revenue Growth

TRDA

124.9%

RNAC

-14.0%

Profitability & performance

Gross Margin

RNAC

0.0%

TRDA

0.0%

ROE

TRDA

-5761.0%

RNAC

-321582.0%

FCF Yield %

RNAC

-37.9%

TRDA

-61.4%

52-Week Performance

TRDA

-8.0%

RNAC

-31.0%

Detailed metrics comparison

RNAC

Cartesian Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Market Cap

RNAC$207M

TRDA$220M

Enterprise Value

RNAC$113M

TRDA$121M

Price

RNAC$7.06

TRDA$5.67

P/E Ratio

RNACN/A

TRDAN/A

P/S Ratio

RNAC140.34x

TRDA46.97x

EV/Sales

RNAC76.18x

TRDA25.79x

EV/EBITDA

RNAC0.00x

TRDA15.47x

P/B Ratio

RNAC296.12x

TRDA0.90x

P/FCF Ratio

RNACN/A

TRDAN/A

EV/FCF

RNAC-1.43x

TRDA-0.89x

PEG Ratio

RNACN/A

TRDAN/A

Forward P/E (NTM)

RNACN/A

TRDAN/A

Forward P/S (NTM)

RNAC473.62x

TRDA5.15x

Revenue (TTM)

RNAC$1M

TRDA$5M

Revenue Growth (YoY)

RNAC-20.7%

TRDA-94.1%

Forward Rev Growth

RNAC-14.0%

TRDA124.9%

Gross Margin (TTM)

RNAC0.0%

TRDA0.0%

Operating Margin (TTM)

RNAC0.0%

TRDA0.0%

EBITDA Margin (TTM)

RNAC-6503.1%

TRDA-3686.8%

Net Margin (TTM)

RNAC-10422.5%

TRDA-3537.7%

FCF Margin (TTM)

RNAC-5322.4%

TRDA-2883.2%

Net Income (TTM)

RNAC$-154M

TRDA$-166M

FCF (TTM)

RNAC$-79M

TRDA$-135M

EPS (TTM)

RNAC-$5.16

TRDA-$3.93

ROE (TTM)

RNAC-321582.0%

TRDA-5761.0%

ROA (TTM)

RNAC-4761.0%

TRDA-4654.0%

ROIC (TTM)

RNAC-321582.0%

TRDA-5761.0%

Cash

RNAC$148M

TRDA$99M

Debt

RNAC$53M

TRDA$0

Net Cash/Debt

RNAC$95M

TRDA$99M

Current Ratio (TTM)

RNAC7.48x

TRDA10.89x

Quick Ratio (TTM)

RNAC7.19x

TRDA10.47x

Debt/Equity (TTM)

RNAC0.28x

TRDA0.00x

Debt/Assets (TTM)

RNAC0.0%

TRDA0.0%

Interest Coverage (TTM)

RNACN/A

TRDAN/A

Net Debt/EBITDA (TTM)

RNAC0.00x

TRDA0.00x

Beta

RNAC0.74

TRDA-0.22

52W Performance

RNAC-31.0%

TRDA-8.0%

YTD Performance

RNAC4.4%

TRDA-43.6%

% from 52W High

RNAC-35.9%

TRDA-65.5%

% from 52W Low

RNAC26.0%

TRDA10.1%

Asset Turnover (TTM)

RNAC0.01x

TRDA0.01x

FCF Yield (TTM)

RNAC-37.9%

TRDA-61.4%

Earnings Yield (TTM)

RNAC-74.3%

TRDA-75.3%

Dividend Yield (TTM)

RNACN/A

TRDAN/A

Rule of 40

RNAC-5,343.1

TRDA-2,977.3

EV/GP/RG

RNACN/A

TRDAN/A

Ticker research

View RNAC research View TRDA research

Metric	RNAC Cartesian Therapeutics Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$207M	$220M
Enterprise Value	$113M	$121M
Price	$7.06	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	140.34x	46.97x
EV/Sales	76.18x	25.79x
EV/EBITDA	0.00x	15.47x
P/B Ratio	296.12x	0.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.43x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	473.62x	5.15x
Revenue & Growth
Revenue (TTM)	$1M	$5M
Revenue Growth (YoY)	-20.7%	-94.1%
Forward Rev Growth	-14.0%	124.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-6503.1%	-3686.8%
Net Margin (TTM)	-10422.5%	-3537.7%
FCF Margin (TTM)	-5322.4%	-2883.2%
Net Income (TTM)	$-154M	$-166M
FCF (TTM)	$-79M	$-135M
EPS (TTM)	-$5.16	-$3.93
ROE (TTM)	-321582.0%	-5761.0%
ROA (TTM)	-4761.0%	-4654.0%
ROIC (TTM)	-321582.0%	-5761.0%
Financial Health
Cash	$148M	$99M
Debt	$53M	$0
Net Cash/Debt	$95M	$99M
Current Ratio (TTM)	7.48x	10.89x
Quick Ratio (TTM)	7.19x	10.47x
Debt/Equity (TTM)	0.28x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.74	-0.22
52W Performance	-31.0%	-8.0%
YTD Performance	4.4%	-43.6%
% from 52W High	-35.9%	-65.5%
% from 52W Low	26.0%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.01x
FCF Yield (TTM)	-37.9%	-61.4%
Earnings Yield (TTM)	-74.3%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-5,343.1	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View RNAC research	View TRDA research